Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Innoviva, Inc. (INVA : NSDQ)
 
 • Company Description   
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.

Number of Employees: 159

 
 • Price / Volume Information   
Yesterday's Closing Price: $21.34 Daily Weekly Monthly
20 Day Moving Average: 574,334 shares
Shares Outstanding: 72.25 (millions)
Market Capitalization: $1,541.72 (millions)
Beta: 0.33
52 Week High: $25.15
52 Week Low: $16.52
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 2.84% 3.58%
12 Week -5.62% -7.61%
Year To Date 6.75% -4.77%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1350 OLD BAYSHORE HIGHWAY SUITE 400
-
BURLINGAME,CA 94010
USA		 ph: 650-238-9600
fax: 650-827-8690		 investors.relations@inva.com http://www.inva.com
 
 • General Corporate Information   
Officers
Pavel Raifeld - Chief Executive Officer
Mark DiPaolo - Chairman
Stephen Basso - Chief Financial Officer
Jules Haimovitz - Director
Sarah Schlesinger - Director

Peer Information
Innoviva, Inc. (AGN.)
Innoviva, Inc. (NVS)
Innoviva, Inc. (NVO)
Innoviva, Inc. (LLY)
Innoviva, Inc. (RHHBY)
Innoviva, Inc. (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 45781M101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/26
Next Expected EPS Date: 11/04/26
Share - Related Items
Shares Outstanding: 72.25
Most Recent Split Date: (:1)
Beta: 0.33
Market Capitalization: $1,541.72 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.50 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $2.30 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/04/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 9.28
Trailing 12 Months: 5.27
PEG Ratio: -
Price Ratios
Price/Book: 1.26
Price/Cash Flow: 4.24
Price / Sales: 3.50
EPS Growth
vs. Year Ago Period: -23.38%
vs. Previous Quarter: 34.09%
Sales Growth
vs. Year Ago Period: 19.25%
vs. Previous Quarter: 22.04%
ROE
06/30/26 - 28.03
03/31/26 - 33.33
12/31/25 - 37.63
ROA
06/30/26 - 20.19
03/31/26 - 22.67
12/31/25 - 23.60
Current Ratio
06/30/26 - 16.01
03/31/26 - 21.13
12/31/25 - 14.64
Quick Ratio
06/30/26 - 15.18
03/31/26 - 20.07
12/31/25 - 13.85
Operating Margin
06/30/26 - 75.76
03/31/26 - 83.97
12/31/25 - 81.07
Net Margin
06/30/26 - 81.19
03/31/26 - 119.89
12/31/25 - 65.92
Pre-Tax Margin
06/30/26 - 95.32
03/31/26 - 142.63
12/31/25 - 79.46
Book Value
06/30/26 - 16.98
03/31/26 - 18.18
12/31/25 - 15.71
Inventory Turnover
06/30/26 - 3.15
03/31/26 - 2.67
12/31/25 - 2.47
Debt-to-Equity
06/30/26 - 0.21
03/31/26 - 0.19
12/31/25 - 0.22
Debt-to-Capital
06/30/26 - 17.33
03/31/26 - 16.13
12/31/25 - 18.02
 

Powered by Zacks Investment Research ©